MCID: RBL001
MIFTS: 62

Rubella

Categories: Rare diseases, Infectious diseases, Fetal diseases, Neuronal diseases

Aliases & Classifications for Rubella

Summaries for Rubella

MedlinePlus : 43 Rubella is an infection caused by a virus. It is usually mild with fever and a rash. About half of the people who get rubella do not have symptoms. If you do get them, symptoms may include A rash that starts on the face and spreads to the body Mild fever Aching joints, especially in young women Swollen glands Rubella is most dangerous for a pregnant woman's baby. It can cause miscarriage or birth defects. Rubella spreads when an infected person coughs or sneezes. People without symptoms can still spread it. There is no treatment, but the measles-mumps-rubella (MMR) vaccine can prevent it. Centers for Disease Control and Prevention

MalaCards based summary : Rubella, also known as german measles, is related to measles and acute disseminated encephalomyelitis, and has symptoms including rash on the face which spreads to the trunk, fever and lymphadenopathy. An important gene associated with Rubella is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and eye, and related phenotypes are Increased shRNA abundance and hematopoietic system

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Rubella virus, which is transmitted by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC : 3 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in a developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia : 76 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 344)
# Related Disease Score Top Affiliating Genes
1 measles 32.7 CD40LG IFNAR2 IL4
2 acute disseminated encephalomyelitis 31.6 HLA-B HLA-DQB1 HLA-DRB1 IL10 MOG
3 mumps 31.5 CD40LG HLA-DRB1 IFNAR2 IL10RB TNF
4 myelitis 30.6 HLA-DPB1 MOG TNF
5 recurrent respiratory papillomatosis 30.5 HLA-DQB1 HLA-DRB1
6 iridocyclitis 30.5 CD40LG HLA-B HLA-DPB1
7 meningitis 30.5 CD40LG IL10 TNF
8 optic neuritis 30.3 HLA-DRB1 MOG TNF
9 tetanus 30.2 CD40LG IL10 IL4
10 anterior uveitis 30.1 HLA-A HLA-B
11 chlamydia 30.1 CD40LG IL10 TNF
12 neuritis 29.9 IL4 MOG TNF
13 poliomyelitis 29.9 IL10 IL4 TNF
14 choroiditis 29.8 IL10 TNF
15 juvenile rheumatoid arthritis 29.8 HLA-DPB1 HLA-DRB1 TNF
16 arthritis 29.7 HLA-DQB1 HLA-DRB1 IL10 TNF
17 pneumonia 29.7 CD40LG IL10 TNF
18 intermediate uveitis 29.6 HLA-B IL10 TNF
19 uveitis 29.5 HLA-B IL10 IL4 TNF
20 myocarditis 29.4 CD40LG HLA-B HLA-DQB1 TNF
21 toxoplasmosis 29.2 CD40LG HLA-DQB1 IL10 IL4 TNF
22 rheumatic disease 28.7 CD40LG HLA-B HLA-DRB1 IL10 TNF
23 diabetes mellitus 28.6 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
24 panuveitis 28.4 CD40LG HLA-B HLA-DQB1 HLA-DRB1 IL10 TNF
25 multiple sclerosis 28.4 HLA-DQB1 HLA-DRB1 IL10 IL4 MOG TNF
26 asthma 27.6 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL4
27 human immunodeficiency virus type 1 27.4 HLA-A HLA-B IL10 TNF TRIM5
28 autoimmune disease 27.1 CD40LG HLA-B HLA-DQB1 HLA-DRB1 IL10 IL4
29 rheumatoid arthritis 27.0 CD40LG HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
30 inflammatory bowel disease 26.8 HLA-B HLA-DQB1 HLA-DRB1 IL10 IL10RB IL4
31 congenital rubella 12.7
32 rubella panencephalitis 12.0
33 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 11.9
34 congenital toxoplasmosis 11.1
35 gianotti crosti syndrome 11.1
36 microcephaly 11.0
37 limbic encephalitis with lgi1 antibodies 10.9 HLA-DQB1 HLA-DRB1
38 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 10.8
39 immunodeficiency 45 10.8
40 congenital intrauterine infection-like syndrome 10.8
41 togaviridae disease 10.8
42 torch syndrome 10.8
43 immune-mediated encephalomyelitis 10.8
44 postinfectious encephalomyelitis 10.8
45 metal allergy 10.8 HLA-DQB1 HLA-DRB1
46 focal epithelial hyperplasia 10.8 HLA-DQB1 HLA-DRB1
47 hypersomnia 10.8 HLA-DQB1 HLA-DRB1
48 lichen planopilaris 10.7 HLA-DQB1 HLA-DRB1
49 type ii mixed cryoglobulinemia 10.7 HLA-DQB1 HLA-DRB1
50 ross river fever 10.7 CD40LG IL10

Graphical network of the top 20 diseases related to Rubella:



Diseases related to Rubella

Symptoms & Phenotypes for Rubella

Symptoms:

12
  • rash on the face which spreads to the trunk
  • fever
  • lymphadenopathy
  • joint pains
  • headache
  • conjunctivitis

UMLS symptoms related to Rubella:


exanthema, fever, pruritus

GenomeRNAi Phenotypes related to Rubella according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 8.92 HLA-B HLA-DPB1 HLA-DQB1 IL4

MGI Mouse Phenotypes related to Rubella:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.28 C1QBP CD40LG HLA-DQB1 IFNAR2 IL10 IL10RB

Drugs & Therapeutics for Rubella

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
2 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
5 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
6 Liver Extracts Phase 4
7
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
8
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 44475014
9
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
10
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
11
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
12
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
13 PENTA Phase 3,Phase 2
14 Vitamin B 12 Phase 3
15 Anti-Bacterial Agents Phase 3,Phase 2
16 Anti-Infective Agents Phase 3,Phase 2
17 Retinol palmitate Phase 3
18 Micronutrients Phase 3
19 Trace Elements Phase 3
20 Vitamins Phase 3
21 Antioxidants Phase 3
22 Protective Agents Phase 3,Phase 2
23 Vitamin B12 Nutraceutical Phase 3
24
Cobalamin Nutraceutical Phase 3 13408-78-1 6438156
25 retinol Nutraceutical Phase 3
26
Altretamine Approved Phase 2 645-05-6 2123
27
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
28
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
29
Mycophenolic acid Approved Phase 2 24280-93-1 446541
30
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
31
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
32
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
33
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
34 Fibrinolytic Agents Phase 2
35 Anticoagulants Phase 2
36 Proteasome Inhibitors Phase 2
37 Prednisolone acetate Phase 2
38 glucocorticoids Phase 2
39 Methylprednisolone acetate Phase 2
40 Methylprednisolone Hemisuccinate Phase 2
41 Gastrointestinal Agents Phase 2
42 Neuroprotective Agents Phase 2
43 Hormone Antagonists Phase 2
44 Hormones Phase 2
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
46 Peripheral Nervous System Agents Phase 2
47 Antibiotics, Antitubercular Phase 2
48 Prednisolone hemisuccinate Phase 2
49 Prednisolone phosphate Phase 2
50 Antiemetics Phase 2

Interventional clinical trials:

(show top 50) (show all 150)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
3 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
4 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
5 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
6 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
7 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
8 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
9 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
10 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
11 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
12 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
13 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
14 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
15 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
16 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
17 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
18 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
19 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
20 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
21 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
22 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
23 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
24 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
25 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Not yet recruiting NCT03071575 Phase 4
26 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
27 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
28 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
29 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
30 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
31 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
32 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
33 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
34 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
35 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
36 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
37 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
38 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
39 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
40 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed NCT00432042 Phase 3
41 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
42 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
43 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
44 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
45 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
46 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
47 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3
48 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3
49 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed NCT00985166 Phase 3
50 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3

Search NIH Clinical Center for Rubella

Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

Anatomical Context for Rubella

The Foundational Model of Anatomy Ontology organs/tissues related to Rubella:

19
Skin

MalaCards organs/tissues related to Rubella:

41
Skin, Eye, Brain, Lymph Node, Heart, Testes, Liver

Publications for Rubella

Articles related to Rubella:

(show top 50) (show all 1337)
# Title Authors Year
1
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with rubella retinopathy. ( 29411259 )
2018
2
Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. ( 29785233 )
2018
3
Rubella viruses shift cellular bioenergetics to a more oxidative and glycolytic phenotype with a strain-specific requirement for glutamine. ( 29950419 )
2018
4
Multimodal imaging in serologically confirmed Rubella retinopathy. ( 29934649 )
2018
5
Social capital, trust in health information, and acceptance of Measles-Rubella vaccination campaign in Tamil Nadu: A case-control study. ( 29943738 )
2018
6
Towards rubella elimination in Japan. ( 29976516 )
2018
7
Rubella infection in pregnancy and congenital rubella in United Kingdom, 2003 to 2016. ( 29766840 )
2018
8
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. ( 29945697 )
2018
9
Decreased antibodies against rubella in previously vaccinated treatment-naA^ve childhood systemic lupus erythematous patients: a prospective case-control study. ( 29741129 )
2018
10
Rubella natural immunity among adolescent girls in Tanzania: the need to vaccinate child bearing aged women. ( 29298693 )
2018
11
Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes. ( 29792776 )
2018
12
Congenital rubella syndrome: A brief review of public health perspectives. ( 29512566 )
2018
13
Myelin Oligodendrocyte Glycoprotein-Independent Rubella Infection of Keratinocytes and Resistance of First-Trimester Trophoblast Cells to Rubella Virus In Vitro. ( 29300335 )
2018
14
Parallel Evolution of Common Allelic Variants Confers Flowering Diversity in <i>Capsella rubella</i>. ( 29764984 )
2018
15
An Intraocular Inflammatory Profile of Rubella Associated Uveitis. ( 29370571 )
2018
16
Imported Congenital Rubella Syndrome, United States, 2017. ( 29553333 )
2018
17
Recognizing Measles, Mumps, and Rubella in the Emergency Department. ( 29715253 )
2018
18
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
19
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7A years of age or older: a phaseA III, randomized study. ( 29902133 )
2018
20
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China. ( 29792546 )
2018
21
Progress Toward Rubella and Congenital Rubella Syndrome Control - South-East Asia Region, 2000-2016. ( 29851943 )
2018
22
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
23
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
24
Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. ( 29420120 )
2018
25
Seroprevalence of HIV, HTLV, CMV, HBV and rubella virus infections in pregnant adolescents who received care in the city of BelAcm, ParA!, Northern Brazil. ( 29769062 )
2018
26
Response to third rubella vaccine dose. ( 29771601 )
2018
27
The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. ( 29865869 )
2018
28
Congenital Rubella ( 29939656 )
2018
29
Measles-Rubella Supplementary Immunization Activity Readiness Assessment - India, 2017-2018. ( 29975677 )
2018
30
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
31
Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016. ( 29965975 )
2018
32
The role of extended and whole genome sequencing for tracking transmission of measles and rubella viruses: report from the Global Measles and Rubella Laboratory Network meeting, 2017. ( 29424220 )
2018
33
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
34
Revaccination with Measles-mumps-rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. ( 29846533 )
2018
35
Measles and Rubella Global Strategic Plan 2012-2020 midterm review. ( 29307367 )
2018
36
Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary. ( 29307368 )
2018
37
An update on epidemiology of congenital rubella syndrome: how far from the World Health Organization goals? ( 28728344 )
2017
38
Complete Genome Sequence of a Genotype 2B Rubella Virus Isolated in South Korea in 2015. ( 28935733 )
2017
39
A New CombinedA VaccineA Against Measles, Mumps, Rubella and Varicella in India. ( 29317560 )
2017
40
Epstein-Barr Virus, but Not Cytomegalovirus, Latency Accelerates the Decay of Childhood Measles and Rubella Vaccine Responses-A 10-Year Follow-up of a Swedish Birth Cohort. ( 29312344 )
2017
41
Micro-planning in a wide age range measles rubella (MR) campaign using mobile phone app, a case of Kenya, 2016. ( 29296151 )
2017
42
Lacrimal drainage anomalies in congenital rubella syndrome. ( 29184387 )
2017
43
Analysis of VSV pseudotype virus infection mediated by rubella virus envelope proteins. ( 28912595 )
2017
44
An infant with congenital rubella syndrome in developing India. ( 29184005 )
2017
45
Pancreatic pseudocyst after measles, mumps, and rubella vaccination. ( 28082255 )
2017
46
Utilization and impact of European immunization week to increase measles, mumps, rubella vaccine uptake in Austria in 2016. ( 28797728 )
2017
47
Can Norway be kept free from rubella and measles? ( 28828847 )
2017
48
The end of measles and congenital rubella: an achievable dream? ( 28067934 )
2017
49
Pivoting from polio eradication to measles and rubella elimination: a transition that makes sense both for children and immunization program improvement. ( 29296145 )
2017
50
Congenital rubella syndrome: an unusual cause of neonatal fulminant hepatic failure. ( 28678001 )
2017

Variations for Rubella

Expression for Rubella

Search GEO for disease gene expression data for Rubella.

Pathways for Rubella

Pathways related to Rubella according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
2
Show member pathways
13.37 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
3
Show member pathways
12.88 HLA-A HLA-B IFNAR2 IL4 TNF
4
Show member pathways
12.88 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
5
Show member pathways
12.6 HLA-A HLA-B IFNAR2 IL10 IL10RB IL4
6
Show member pathways
12.6 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
7 12.52 C1QBP CD40LG IL10 IL4 TNF
8
Show member pathways
12.48 HLA-A HLA-B IFNAR2 TNF
9
Show member pathways
12.47 HLA-A HLA-B IFNAR2 IL4 TNF
10
Show member pathways
12.45 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL4 TNF
11
Show member pathways
12.42 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IFNAR2
12
Show member pathways
12.35 CD40LG IL10 IL4 TNF
13 12.35 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
14 12.24 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL10RB TNF
15 12.22 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
16 12.14 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
17
Show member pathways
12.14 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1
18
Show member pathways
12.13 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10RB
19 12.07 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
20
Show member pathways
12.03 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10 IL10RB
21 11.91 IL10 IL4 TNF
22 11.91 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL4 TNF
23 11.9 IL10 IL4 TNF
24
Show member pathways
11.89 HLA-A HLA-DRB1 IL4
25
Show member pathways
11.87 HLA-DPB1 HLA-DQB1 HLA-DRB1
26 11.84 HLA-DPB1 HLA-DQB1 HLA-DRB1
27 11.83 HLA-DPB1 HLA-DQB1 HLA-DRB1 TNF
28 11.72 IL10 IL4 TNF
29
Show member pathways
11.69 CD40LG IL4 TNF
30 11.62 HLA-DPB1 HLA-DQB1 HLA-DRB1 IL10
31 11.6 CD40LG IL10 IL4
32
Show member pathways
11.58 HLA-A IFNAR2 TNF
33 11.55 IL10 IL10RB IL4 TNF
34 11.48 CD40LG IL10 TNF
35 11.33 IL10 IL10RB TNF
36 11.31 HLA-DRB1 IL10 IL4 TNF
37 11.16 CALR HLA-A HLA-B

GO Terms for Rubella

Cellular components related to Rubella according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.91 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
2 cell surface GO:0009986 9.76 C1QBP CALR CD40LG HLA-A HLA-B HLA-DPB1
3 external side of plasma membrane GO:0009897 9.72 CALR CD40LG HLA-DRB1 MOG TNF
4 trans-Golgi network membrane GO:0032588 9.67 HLA-DPB1 HLA-DQB1 HLA-DRB1
5 phagocytic vesicle membrane GO:0030670 9.63 CALR HLA-A HLA-B
6 endocytic vesicle membrane GO:0030666 9.61 HLA-DPB1 HLA-DQB1 HLA-DRB1
7 transport vesicle membrane GO:0030658 9.58 HLA-DPB1 HLA-DQB1 HLA-DRB1
8 clathrin-coated endocytic vesicle membrane GO:0030669 9.54 HLA-DPB1 HLA-DQB1 HLA-DRB1
9 MHC class I protein complex GO:0042612 9.48 HLA-A HLA-B
10 MHC class II protein complex GO:0042613 9.43 HLA-DPB1 HLA-DQB1 HLA-DRB1
11 ER to Golgi transport vesicle membrane GO:0012507 9.35 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
12 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 CALR HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
13 plasma membrane GO:0005886 10.26 C1QBP CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1

Biological processes related to Rubella according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.95 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DRB1 TRIM5
2 cytokine-mediated signaling pathway GO:0019221 9.91 IFNAR2 IL10 IL10RB IL4 TNF
3 defense response to virus GO:0051607 9.9 IFNAR2 IL10RB TRIM22 TRIM5
4 T cell receptor signaling pathway GO:0050852 9.87 HLA-DPB1 HLA-DQB1 HLA-DRB1 MOG
5 response to virus GO:0009615 9.85 IFNAR2 TNF TRIM22
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 CD40LG TNF TRIM22 TRIM5
7 response to organic substance GO:0010033 9.84 CALR IL10 TNF
8 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.84 HLA-DPB1 HLA-DQB1 HLA-DRB1
9 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.82 CALR HLA-A HLA-B
10 B cell differentiation GO:0030183 9.82 CD40LG IL10 IL4
11 type I interferon signaling pathway GO:0060337 9.81 HLA-A HLA-B IFNAR2
12 regulation of immune response GO:0050776 9.8 CD40LG HLA-A HLA-B IL4 MOG
13 viral process GO:0016032 9.8 C1QBP HLA-A HLA-B HLA-DRB1 MOG TRIM22
14 positive regulation of T cell proliferation GO:0042102 9.79 CD40LG HLA-DPB1 IL4
15 positive regulation of DNA binding transcription factor activity GO:0051091 9.76 IL10 TNF TRIM22 TRIM5
16 negative regulation of growth of symbiont in host GO:0044130 9.67 IL10 TNF
17 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.67 CALR HLA-A HLA-B
18 T cell costimulation GO:0031295 9.67 CD40LG HLA-DPB1 HLA-DQB1 HLA-DRB1
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.66 IL10 TNF
20 negative regulation of interleukin-12 production GO:0032695 9.65 C1QBP IL10
21 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.65 HLA-A HLA-B
22 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
23 positive regulation of dendritic cell chemotaxis GO:2000510 9.63 C1QBP CALR
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.62 IL10 IL4
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
26 type 2 immune response GO:0042092 9.61 IL10 IL4
27 negative regulation of interferon-gamma production GO:0032689 9.61 C1QBP HLA-DRB1 IL10
28 protection from natural killer cell mediated cytotoxicity GO:0042270 9.59 HLA-A HLA-B
29 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.58 HLA-DQB1 HLA-DRB1
30 regulation of immunoglobulin secretion GO:0051023 9.58 CD40LG TNF
31 regulation of isotype switching GO:0045191 9.56 IL10 IL4
32 antigen processing and presentation GO:0019882 9.55 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1
33 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
34 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.52 HLA-DQB1 HLA-DRB1
35 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.5 HLA-DPB1 HLA-DQB1 HLA-DRB1
36 interferon-gamma-mediated signaling pathway GO:0060333 9.5 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1 TRIM22
37 immune response GO:0006955 9.4 C1QBP CD40LG HLA-A HLA-B HLA-DPB1 HLA-DQB1

Molecular functions related to Rubella according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.26 HLA-DQB1 HLA-DRB1
2 cytokine activity GO:0005125 9.26 CD40LG IL10 IL4 TNF
3 complement component C1q binding GO:0001849 9.16 C1QBP CALR
4 peptide antigen binding GO:0042605 9.02 HLA-A HLA-B HLA-DPB1 HLA-DQB1 HLA-DRB1

Sources for Rubella

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....